Application 1089
Brachytherapy for the treatment of prostate cancer
Brachytherapy for the treatment of prostate cancer
Application No. | 1089 |
| Application Name | Brachytherapy for the treatment of prostate cancer |
| Advisory Panel | Dr Michael Kitchener (Chair and MSAC member) Dr Ross Cartmill (co-opted member) Dr Graeme Dickie (co-opted member) Professor Gillian Duchesne (co-opted member) Dr Alastair Tulloch (co-opted member) Mr Clive Deverall (Consumers' Health Forum of Australia nominee) |
| Date Received by MSAC Secretariat | 13 October 2004 |
| Stage 1 - Eligibility | Eligible |
| Stage 2 - Assessment | Completed |
| Stage 3 - Formulation of Advice to the Minister | This assessment was considered by the MSAC at the 18 May 2005 meeting. Following reassessment of further evidence pertaining to the safety, effectiveness and cost-effectiveness of brachytherapy for the treatment of prostate cancer, interim funding should continue for patients with prostate cancer meeting the following criteria: - at clinical stages T1 and T2 with Gleason scores of less than or equal to 6, PSA of less than or equal to 10ng/ml, gland volume less than 40cc and with a life expectancy of more than 10 years; and - where treatment is conducted at approved sites. |
| Stage 4 - Decision | Endorsed by the Minister for Health and Ageing 28 November 2005 |
| Stage 5 - Implementation |  |
Page currency, Latest update: 31 March, 2008
